Looking Ahead and Key Takeaways

Elizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.

EP: 1.Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

EP: 2.Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

EP: 3.Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

EP: 4.Optimizing Regimens and Managing Adverse Events in TIE NDMM

Now Viewing

EP: 5.Looking Ahead and Key Takeaways

EP: 6.Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP: 7.Overview of PERSEUS, IsKia, and GMMG-HD7

EP: 8.Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

1. Please comment on the most significant advancements on the horizon for frontline therapy in both transplant-ineligible patients with newly diagnosed multiple myeloma. 
2. Provide your key takeaways from the latest clinical trial data and how you anticipate these findings will impact your day-to-day clinical practice.

Related Videos